EN PL
 
EN PL
Bieżący numer
Archiwum
Online first
O czasopiśmie
Dla autorów
Książki i Konferencje
4/2016 vol. 54
Pobierz cytowanie
PRACA PRZEGLĄDOWA
Choroby reumatyczne indukowane lekami i czynnikami środowiskowymi: aktualny stan wiedzy. Część druga.
Karolina Niklas
,
 
Arkadiusz A. Niklas
,
 
Dominik Majewski
,
 
Mariusz J. Puszczewicz
 
 
 
Więcej
Ukryj
 
Data nadesłania: 24-05-2016
 
 
Data ostatniej rewizji: 19-08-2016
 
 
Data akceptacji: 23-08-2016
 
 
Data publikacji online: 05-10-2016
 
 
Data publikacji: 31-08-2016
 
 
Reumatologia 2016;54(4):165-169
DOI: https://doi.org/10.5114/reum.2016.62470
 
 
Artykuł (PDF)
Referencje (38)
 
SŁOWA KLUCZOWE
rheumatic diseases
drugs
environmental factors
 
DZIEDZINY
Reumatoidalne zapalenie stawów - etiologia, patogeneza, obraz kliniczny i leczenie
SLE, zespół Sjögrena i zespół antyfosfolipidowy - etiologia, patogeneza, obraz kliniczny i leczenie
Twardzina układowa, myositis i powiązane zespoły - etiologia, patogeneza, obraz kliniczny i leczenie
Zapalenia naczyń - etiologia, patogeneza, obraz kliniczny i leczenie
 
STRESZCZENIE
The majority of rheumatic diseases belong to the group of autoimmune diseases and are associated with autoantibody production. Their etiology is not fully understood. Certain medications and environmental factors may have an influence on the occurrence of rheumatic diseases. Establishing a cause-effect relationship between a certain factor and disease induction is not always simple. It is important to administer the drug continuously or monitor exposure to a given factor in the period preceding the onset of symptoms. The lack of early diagnosed autoimmune disease, or finally the lack of symptoms within a few weeks/months after discontinuation of the drug/cessation of exposure, is also important.
The most frequently mentioned rheumatic diseases caused by drugs and environmental factors include systemic lupus erythematosus (SLE), scleroderma, systemic vasculitis, polymyositis, dermatomyositis, and Sjögren’s syndrome.
The objective of this study is to summarize current knowledge on rheumatic diseases induced by drugs and environmental factors.
REFERENCJE (38)
1.
Uyar M, Elbek O, Bakır K, et al. Churg-Strauss syndrome related to montelukast. Tuberk Toraks 2012; 60: 56-58.
Google Scholar
 
 
2.
Bukhari M. Drug-induced rheumatic diseases: a review of published case reports from the last two years. Curr Opin Rheumatol 2012; 24: 182-186.
Google Scholar
 
 
3.
Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep 2015; 17: 71.
Google Scholar
 
 
4.
D’Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 2000; 112-113: 421-432.
Google Scholar
 
 
5.
Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20: 35-39.
Google Scholar
 
 
6.
Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405-413.
Google Scholar
 
 
7.
Muńoz-Grajales C, Pineda JC. Pathophysiological relationship between infections and systemic vasculitis. Autoimmune Dis 2015; 2015: 286783.
Google Scholar
 
 
8.
D’Alessandro M, Buoncompagni A, Minoia F, et al. Cytomegalovirus-related necrotising vasculitis mimicking Henoch-Schönlein syndrome. Clin Exp Rheumatol 2014; 32 (3 Suppl 82): S73-75.
Google Scholar
 
 
9.
Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010; 9: A293-298.
Google Scholar
 
 
10.
Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011; 70 Suppl 1: i59-63.
Google Scholar
 
 
11.
Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 2013; 12: 1129-1135.
Google Scholar
 
 
12.
Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37: 1549-1550.
Google Scholar
 
 
13.
Liu SW, Velez NF, Lam C, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol 2013; 149: 1204-1208.
Google Scholar
 
 
14.
Hahn M, Sriharan K, McFarland MS. Gemfibrozil-induced myositis in a patient with normal renal function. Ann Pharmacother 2010; 44: 211-214.
Google Scholar
 
 
15.
Niklas K, Niklas A, Puszczewicz M, et al. Polymyositis induced by atorvastatin. Kardiol Pol 2015; 73: 1336.
Google Scholar
 
 
16.
Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008; 59: 872-880.
Google Scholar
 
 
17.
Yang CY, Park SA, Kim HS, et al. Polymyositis in patients taking antiviral clevudine therapy: a report of two cases. NeuroRehabilitation 2010; 26: 159-162.
Google Scholar
 
 
18.
Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015; 151: 195-199.
Google Scholar
 
 
19.
Tong PL, Yu LL, Chan JJ. Drug-induced dermatomyositis after zoledronic acid. Australas J Dermatol 2012; 53: e73-75.
Google Scholar
 
 
20.
Pignone A, Fiori G, Del Rosso A, et al. The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. Autoimmun Rev 2002; 1: 226-232.
Google Scholar
 
 
21.
Majewski D, Puszczewicz M, Kołczewska A. Differential diagnosis of polymyositis. Case report. Ann Acad Med Stetin 2010; 56 Suppl 1: 66-69.
Google Scholar
 
 
22.
Takenaka K, Miyabe Y, Kasai S, et al. Polymyositis in a father and his son; a case report. Nihon Rinsho Meneki Gakkai Kaishi 2012; 35: 144-149.
Google Scholar
 
 
23.
Darwaza A, Lamey PJ, Connell JM. Hydrallazine-induced Sjögren’s syndrome. Int J Oral Maxillofac Surg 1988; 17: 92-93.
Google Scholar
 
 
24.
Kivity S, Arango MT, Ehrenfeld M, et al. Infection and autoimmunity in Sjogren’s syndrome: A clinical study and comprehensive review. J Autoimmun 2014; 51: 17-22.
Google Scholar
 
 
25.
Rothschild B. Acrylamine-induced autoimmune phenomena. Clin Rheumatol 2010; 29: 999-1005.
Google Scholar
 
 
26.
Chang K, Yang SM, Kim SH, et al. Smoking and rheumatoid arthritis. Int J Mol Sci 2014; 15: 22279-22295.
Google Scholar
 
 
27.
Essouma M, Noubiap JJ. Is air pollution a risk factor for rheumatoid arthritis? J Inflamm (Lond) 2015; 12: 48.
Google Scholar
 
 
28.
Badran Z, Struillou X, Verner C, et al. Periodontitis as a risk factor for systemic disease: are microparticles the missing link? Med Hypotheses 2015; 84: 555-556.
Google Scholar
 
 
29.
Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol 2014; 66: 768-769.
Google Scholar
 
 
30.
Zandman-Goddard G, Solomon M, Rosman Z, et al. Environment and lupus-related diseases. Lupus 2012; 21: 241-250.
Google Scholar
 
 
31.
Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13: 736-741.
Google Scholar
 
 
32.
Meyer A, Rotman-Pikielny P, Natour A, et al. Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. Isr Med Assoc J 2010; 12: 638-639.
Google Scholar
 
 
33.
Ghattaura A, Eley KA, Molenaar E, et al. A case of extensive ulcerating vasculitis following a BCG vaccination. J Plast Reconstr Aesthet Surg 2009; 62: e286-289.
Google Scholar
 
 
34.
Le Hello C, Cohen P, Bousser MG, et al. Suspected hepatitis B vaccination related vasculitis. J Rheumatol 1999; 26: 191-194.
Google Scholar
 
 
35.
Stübgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev 2014; 13: 31-39.
Google Scholar
 
 
36.
Soriano A, Afeltra A, Shoenfeld Y. Immunization with vaccines and Sjögren’s syndrome. Expert Rev Clin Immunol 2014; 10: 429-435.
Google Scholar
 
 
37.
Shoenfeld Y, Agmon-Levin N. ‘ASIA’-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8.
Google Scholar
 
 
38.
Parks CG, Miller FW, Pollard KM, et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci 2014; 15: 14269-14297.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
Wyślij mailem
ARTYKUŁ POWIĄZANY
Ocular involvement in rheumatic diseases
Programy doskonalenia zawodowego
Reumatologia w praktyce lekarza rodzinnego
Działania naprawcze i projekty w toku
Lobbing organizacji chorych wśród polskich europarlamentarzystów
Czym jest zdrowie publiczne w Polsce w roku 2006?
Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
Indeksy
 
Indeks słów kluczowych
Indeks dziedzin
Indeks autorów
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top